Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada

Andrew Blauvelt,¹ Saakshi Khattri,² Phoebe Rich,³ Ronald Vender,⁴ Kenneth B. Gordon,⁵ Balint Szilagyi,⁶ Heather Herr,⁷ Bertram Knapp,⁶ Delphine Deherder,⁸ Sarah Kavanagh,⁹ Kim Papp^{10,11}

¹Blauvelt Consulting, LLC, Annapolis, MD, USA; ¹The Mount Sinai Hospital, New York, NY, USA; ³Oregon Dermatology and Research Center, Portland, OR, USA; ⁴Dermatrials Research Inc., Hamilton, ON, Canada; ⁵Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; ⁴UCB, Monheim am Rhein, Germany; ¬UCB, Smyrna, GA, USA; ⁴UCB, Braine-l'Alleud, Belgium; 9UCB, Morrisville, NC, USA; 10 Probity Medical Research and Alliance Clinical Trials, Waterloo, ON, Canada; 11 Division of Dermatology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Objective

To evaluate the long-term efficacy and safety of bimekizumab (BKZ) treatment through 5 years in patients with moderate to severe plaque psoriasis from the US

Background

- Given the chronic nature of psoriasis, and the loss of response observed with biologic therapies over time, it is crucial to establish the long-term efficacy and safety of biologic
- Treatment with BKZ, a monoclonal immunoglobulin (lg)G1 antibody that inhibits interleukin (IL)-17F in addition to IL-17A, has previously demonstrated maintenance of high response rates through 4 years in patients with moderate to severe plague psoriasis.^{2,3}

Methods

- US/Canadian patients who completed the 52-week BE VIVID and 56-week BE SURE and BE READY phase 3 trials, and the 144-week BE BRIGHT open-label extension (OLE; 4 years' total treatment), could enter a second 48-week OLE (OLE2; Figure 1).4-7
- Patients entered the BE BRIGHT OLE2 with or without a treatment break, since some patients had completed the study before it was extended. Only patients who were randomized to BKZ at baseline and received BKZ continuously into OLE2, without a treatment break, were included in this analysis. All included patients received BKZ every 8 weeks (Q8W) on OLE2 entry (Figure 1).
- Efficacy data and treatment-emergent adverse events (TEAEs; incidence/100 patient-years [PY]) are reported over 5 years of BKZ treatment (to OLE2 Week 48; 244 or 248 weeks' total treatment)
- Data are reported in patients irrespective of dose (BKZ Total) and in patients who received BKZ 320 mg every 4 weeks (Q4W) to Week 16 then Q8W thereafter (BKZ Q4W/Q8W; the approved dosing regimen for most patients with psoriasis).8
- Patients discontinuing treatment due to lack of efficacy or treatment-related adverse events were considered non-responders; multiple imputation was used for other missing data (modified non-responder imputation [mNRI])

Results

Baseline characteristics

- Of the 153 US/Canadian patients analyzed, 52 patients received BKZ Q4W/Q8W.
- Baseline characteristics are shown in **Table 1**.

Efficacy

- At Year 1 (Week 52) and Year 5 (Week 244), respectively, 92.8% and 84.9% of BKZ Total patients achieved 90% improvement in Psoriasis Area and Severity Index (PASI 90); among the BKZ Q4W/Q8W subset, 96.2% and 88.5% of patients achieved PASI 90 (Figure 2A).
- At Year 1 and Year 5, respectively, 75.2% and 67.7% of BKZ Total patients achieved 100% improvement in Psoriasis Area and Severity Index (PASI 100); among the BKZ Q4W/Q8W subset, 78.8% and 76.9% of patients achieved PASI 100 (Figure 2B).
- Investigator's Global Assessment (IGA) 0/1 achievement rates followed a similar trend to that of PASI 90; Dermatology Life Quality Index (DLQI) 0/1 achievement rates were similar at Year 1 and Year 5 for BKZ Total patients, but were numerically higher for BKZ Q4W/Q8W patients at Year 5 versus Year 1 (Figures 2C-D).

- Over 5 years, serious TEAEs (3.6/100 PY) and discontinuations due to TEAEs (0.3/100 PY) were low; no deaths occurred. The most common TEAEs were nasopharyngitis (9.7/100 PY), oral candidiasis (7.6/100 PY), and coronavirus infection (6.1/100 PY), in line with BKZ's known safety profile (Table 2).9
- The vast majority (99.3%) of oral candidiasis events were mild to moderate; none led to discontinuation.
- BKZ Q4W/Q8W safety data were generally similar to BKZ Total data, although the patient group was small, so results should be interpreted with caution (Table 2).

Conclusions

Bimekizumab demonstrated high rates of clinical and health-related quality of life responses, which were highly durable to Year 5, in patients from the US and Canada with moderate to severe plague psoriasis.


Bimekizumab was well-tolerated in this patient subgroup, with no unexpected

Summary

High clinical and health-related quality of life responses to bimekizumab were maintained through 5 years in patients from the US and Canada with moderate to



BE BRIGHT study design






[a] BE VIVID did not include an option for Q8W dosing of BKZ during the maintenance period; [b] BE VIVID lasted 52 weeks and BE SURE and BE READY lasted 56 weeks; [c] All patients were re-assigned to BKZ Q8W at Week 100/104 (OLE Week 48) or the next scheduled visit via protocol amendment: Idl 46 patients had a treatment break and are not included in this analysis

Baseline characteristics

	BKZ Total	BKZ Q4W/Q8W
	N=153	N=52
Age (years), mean (SD)	45.7 (13.6)	46.8 (15.5)
Sex, male, n (%)	102 (66.7)	35 (67.3)
Racial group, white, n (%)	124 (81.0)	44 (84.6)
Weight ^a (kg), mean (SD)	93.9 (22.6)	90.4 (21.3)
BMI ^a (kg/m ²), mean (SD)	31.7 (7.0)	30.4 (6.3)
Duration of psoriasis (years), mean (SD)	19.0 (13.8)	18.9 (14.0)
PASI, mean (SD)	19.7 (6.8)	18.4 (5.8)
BSA (%), mean (SD)	24.4 (14.6)	20.1 (10.7)
IGA , n (%)	į	
3: moderate	104 (68.0)	38 (73.1)
4: severe	49 (32.0)	14 (26.9)
DLQI total , mean (SD)	10.5 (6.0)	11.1 (5.8)
Any prior systemic therapy, n (%)	100 (65.4)	31 (59.6)
Any prior biologic therapy, n (%)	47 (30.7)	11 (21.2)
anti-TNF	24 (15.7)	7 (13.5)
anti-IL-17	18 (11.8)	4 (7.7)
anti-IL-23	4 (2.6)	0 (0.0)
anti-IL-12/23	8 (5.2)	1 (1.9)


[a] The mean weight of US/Canadian patients in OLE2 was numerically higher than the global BE BRIGHT population (mea 29.3 ± 6.2 kg/m² [BKZ Q4W/Q8W]).

Efficacy outcomes through 5 years (mNRI)




→ BKZ Q4W/Q8W (N=52)

→ BKZ Total (N=153)



OLE1

Double-blinded





s. Week 56 data were not included. In the point representing Week 48 in BE SURE and BE READY and Week 52 in BE VIVID, due to a lack of common timepoints at which DLQI was assessed

OLE2

non-melanoma skin cancer; OLE: open-label extension; OLE1 (rist/second open-label extension; OLE1/2: first/second open-label extension; PASI: Psoriasis Area and Severity Index; PY: patient-years; Q4W: every 8 weeks; SD: standard deviation; SIB: suicidal ideation and behavior; TEAE: treatment-emergent adverse event; TNF: References: "Warren RB et al. J Invest Dermatol 2015;135:2632-2640; "Actom R et al. Front Immunol 2020;11:1894; "Thaçi D et al. Front Immunol 2021;385:130-41 (NCT03412747); "Gordon KB et al. J Invest Dermatol 2015;385:130-46 (NCT03410992); "Strober B et al. Br J Dermatol 2023;188:749-59 (NCT03598790); "Food and Drug Ad

Bimekizumab Prescribing Information, 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761151s000lbl.pdf [Accessed June 2025]; °Gordon KB et al. AAD 2024; Late-Breaking Presentation of 041013. Author Contributions: Substantial Contributions to study conception/design, or acquisition/analysis/interpretation of 041013. Author Contributions: Substantial Contributions to study conception/design, or acquisition/analysis/interpretation of 041013. Author Contributions: Substantial Contributions to study conception/design, or acquisition/analysis/interpretation of 041013. Author Contributions: Substantial Contributions to study conception/design, or acquisition/analysis/interpretation of 041013. Author Contributions: Substantial Contributions to study conception/design, or acquisition/analysis/interpretation of 041013. Author Contributions: Substantial Contributions to study conception/design, or acquisition/analysis/interpretation of 041013. Author Contributions: Substantial Contributions to study conception/design, or acquisition/analysis/interpretation of 041013. Author Contributions: Substantial Contributions: Sub Boehringer Ingelheim, Bristol Meyers Squibb, Celltrion, Corvus, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Immunovant, Incyte, IQVIA, Johnson & Johnson, EO Pharma, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Syncona, Takeda, UCB, and Union; acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Meyers Squibb, Dermavant, Eli Lilly and Company, Galderma, Incyte, Johnson & Johnson, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB; and owns stock in Lipidio and Oruka. SKh: Received research grants from AbbVie, Acelyrin, Bristol Meyers Squibb, and Incyte; consulting/advisory boards and Incyte; Consultant for Bristol Meyers Squibb, Celltrion, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Sun Pharma, Eli Lilly and Company, Johnson & Johnson, Eli Lilly and Company, Johnson & Johnson, Eli Lilly and Company, Johnson & Johnson, Eli Lilly and Company, Eli Lilly and Company, Johnson & Johnson, Eli Lilly and Company, Johnson & Johnson, Eli Lilly and Company, Eli Lilly and Company, Eli Lilly and Compa Dermavant, Dermira, DiCE Therapeutics, Eli Lilly and Company, Galderma, Incyte, Johnson & Johnson, LEO Pharma, Meiji Seika Pharma, Nimbus Therapeutics, Roundi-Aventis, Pfizer, Sandoz, Sanofi-Aventis, Pfizer, Sundoz, Sanofi Novartis, Onward Medical, PharPoint Research, Summit Analytical, Therini Bio, Tonix Pharmaceuticals, Dermavant, Dermira, Celtrion, Concert Pharmaceuticals, Tornado Therapeutics, UCB, Whitsell Innovations, Worldwide Clinical Trials, and Zosano Pharma, Celtrion, Concert Pharmaceuticals, Dermavant, Dermira, DicE Therapeutics, Eli Lilly and Company, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Johnson & Johnson, Kymab, Kyowa Hakko Kirin, LEO Pharma, Mitsubishi Phar



Rates of TEAEs through 5 years

EAIR/100 PY (95% CI)	BKZ Total N=153 757 PY ^a	BKZ Q4W/Q8W N=52 259 PY ^b
TEAE summary		
Any TEAE	171.4 (145.0, 201.2)	199.3 (147.9, 262.7)
Serious TEAEs	3.6 (2.3, 5.3)	2.0 (0.7, 4.8)
Discontinuation due to TEAEs in OLE2	0.3 (0.0, 1.0)	0.4 (0.0, 2.2)
Severe TEAEs	4.0 (2.7, 5.8)	3.2 (1.4, 6.4)
TEAEs leading to death in OLE2	0	0
Most common TEAEs		
Nasopharyngitis	9.7 (7.3, 12.7)	9.5 (5.6, 15.0)
Oral candidiasis	7.6 (5.5, 10.2)	9.4 (5.6, 14.9)
Coronavirus infection	6.1 (4.4, 8.2)	5.3 (2.8, 9.1)
Upper respiratory tract infection	5.8 (4.0, 8.0)	6.8 (3.7, 11.3)
TEAEs of interest		
Serious infections	1.2 (0.6, 2.3)	0.8 (0.1, 2.9)
Active tuberculosis	1	. 0

TEAEs of interest		
Serious infections	1.2 (0.6, 2.3)	0.8 (0.1, 2.9)
Active tuberculosis	0	0
Fungal infections	9.4 (7.0, 12.3)	10.9 (6.7, 16.8)
Candida infections	7.6 (5.5, 10.2)	9.5 (5.6, 14.9)
Oral candidiasis	7.6 (5.5, 10.2)	9.4 (5.6, 14.9)
Definite or probable adjudicated IBD	0.1 (0.0, 0.7)	0
Adjudicated MACE	0.8 (0.3, 1.8)	0.4 (0.0, 2.2)
Malignancies	0.7 (0.2, 1.6)	0.8 (0.1, 2.9)
Excluding NMSC	0.3 (0.0, 1.0)	0.4 (0.0, 2.2)
Adjudicated SIB	0	0
Neutropenia	0.1 (0.0, 0.7)	0
ALT or AST >3x ULN	1.1 (0.5, 2.2)	0.4 (0.0, 2.2)
ALT or AST >5x ULN ^c	0.4 (0.1, 1.2)	0
Serious hypersensitivity reactions	0	0
Injection site reactions	2.1 (1.2, 3.5)	3.4 (1.5, 6.8)



To receive a copy of this poster, scan the QR code Link expiration: